Últimas noticias sobre Exela Technologies (OTC:XELAP) Bolsa

Exela Technologies Inc is a business process automation (BPA) leader combining industry-specific and multi-industry enterprise software and solutions. The company's BPA suite of solutions is deployed in banking, healthcare, insurance, and other industries. The company's segment includes Information and Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal and Loss Prevention Services (LLPS). It generates maximum revenue from the ITPS segment.

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Exela Technologies Inc

WIIM

KDLY

KindlyMD shares are trading higher after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.

<ul>
<li>MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025</li>
<li>MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and&nbsp;co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025.</li>
<li>MET-097o, an oral formulation of MET-097i, has been accelerated&nbsp;and alternate oral candidate MET-224o is on track, with four-week data&nbsp;for selected lead expected in late 2025.</li>
</ul>

Earnings

News

MTSR

Metsera Q1 2025 EPS $(1.03) Beats $(1.04) Estimate, $588M Cash And Cash Equivalents Support Runway Into 2027

Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene &amp; Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13th – 17th at the New Orleans Ernest N. Morial Convention Center.
Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope&#x2122; protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak&#x2122; GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo&#x2122; System will also be featured, with this state-of-the-art instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run.

TECH

Bio-Techne To Showcase Latest Spatial Biology And Cell And Gene Therapy Workflow Solutions At ASGCT 2025 Meeting

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Price Target

Reiteration

Analyst Ratings

INSM

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.10) by 70 percent. This is a 13.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $821.79 million which beat the analyst consensus estimate of $774.38 million by 6.12 percent. This is a 6.51 percent decrease over sales of $879.03 million the same period last year.

Earnings Beats

Earnings Misses

Advantage Solutions Q1 EPS $(0.17) Misses $(0.10) Estimate, Sales $821.79M Beat $774.38M Estimate

Biotech

General

RNTX

Rein Therapeutics Initiates RENEW Phase 2 Trial Ff LTI-03 For Patients With Idiopathic Pulmonary Fibrosis

Sprott Physical Uranium Trust, On Behalf Of Sprott Physical Uranium Trust, Completes $25.55M Non-Brokered Private Placement

Sionna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.44) by 40.91 percent.

SION

Sionna Therapeutics Q1 EPS $(0.62) Misses $(0.44) Estimate

D. Boral Capital analyst Jason Kolbert initiates coverage on NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy rating and announces Price Target of $14.

Initiation

NRSN

D. Boral Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $14

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally to almost $106,000 may not yet be its peak, with technical models and macro flows aligning to support a near-term price target of $122,000, <a href="https://www.benzinga.com/money/bitcoin-price-prediction">according to a report</a>.
The move follows a well-defined breakout above the $84,500 level in mid-April and has been reinforced by strong spot buying and expanding institutional interest, according to a market update from May 12.
What Happened: This week's <a href="https://blog.coinshares.com/volume-233-digital-asset-fund-flows-weekly-report-f38946027bd6">data</a> from CoinShares further underpins the bullish thesis.
Digital asset investment products recorded $882 million in inflows globally last week, marking four consecutive weeks of growth and bringing year-to-date inflows to $6.7 billion. 
Bitcoin accounted for $867 million of that, continuing to dominate institutional allocations. 
Notably, <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">U.S.-listed Bitcoin ETFs</a> have now amassed a cumulative $62.9 billion in net inflows since launching in January 2024, a record high.
Regionally, inflows were led by the United States ($840 million), followed by Germany and Australia, while Canada and Hong Kong saw small outflows. 
CoinShares attributes the increase in inflows to "a global rise in M2 money supply, stagflationary risks in the US and several US states approving Bitcoin as a strategic reserve asset."
Also Read: <a href="https://www.benzinga.com/markets/25/05/45332547/ethereum-explodes-25-higher-to-2-400-notches-largest-1-day-gain-in-4-years">Ethereum Explodes 25% Higher To $2,400, Notches Largest 1-Day Gain In 4 Years</a>
What Experts Are Saying: From a market structure perspective, Bitcoin&#8217;s rally has unfolded in $16,000 increments, with clear resistance and support levels established at $73,000, $84,500, and $95,000, all of which have been either broken or successfully retested, according to 10x Research.
After peaking at close to $106,000, analysts suggest that momentum remains intact, with technical models now pointing toward $122,000 as the next major target.
The trade thesis has been driven by long call spreads, specifically $100,000/$110,000, capitalizing on low implied volatility, which remains around 45% despite the ongoing price surge. 
"Being long on call spreads was the superior risk-adjusted trade," the report stated. 
Traders are now advised to consider rolling into higher strikes such as $110,000/$120,000.
Interestingly, the rally to $95,000 was driven not by leveraged futures but primarily by spot buying, notably from institutional players like Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and ETF inflows, while many futures traders attempted to short the move. 
The failure of these counter-trades has added further weight to the bullish breakout.
Macroeconomic conditions have also provided a supportive backdrop. 
Fed Chair Jerome Powell recently downplayed tariff-related inflation as "potentially a one-time event," while tomorrow's CPI print is expected to hold steady at 2.4%. 
If inflation remains below 3% and U.S. economic data shows resilience, the incentive to exit positions may remain low. Political developments, particularly a pivot toward tax cuts and deregulation, are also cited as tailwinds.
Though Ethereum saw a significant price increase during the same period, its fund inflows remained limited at just $1.5 million, per CoinShares. 
Meanwhile, Sui (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) attracted $11.7 million in inflows last week, surpassing Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), which saw outflows of $3.4 million. 
On a year-to-date basis, Sui has now pulled in $84 million, overtaking Solana's $76 million.
Despite a complex macro backdrop, Bitcoin&#8217;s price action remains spot-driven and momentum-led, with the combination of technical breakouts and record-setting institutional flows making the $122,000 target increasingly viable.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45326910/senate-democrats-question-binance-trump-stablecoin-ties-amid-blocked-stablecoin-legislation">Senate Democrats Question Binance-Trump Stablecoin Ties Amid Blocked Stablecoin Legislation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$SOL

$SUI

MSTR

Bitcoin Taps $105,000: Here's When It Could Hit $122,000

MAIN

Main Street Says Recently Fully Exited Its Debt Investments And Partially Exited Equity Investment In Nebraska Vet AcquireCo, LLC, dba Heritage Vet Partners, Generating $55.5M Realized Gain

Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 28.57 percent decrease over losses of $(0.77) per share from the same period last year.

LXEO

Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate

Macro Economic Events

Global

Economics

Bessent Says We're Negotiating To Prevent Workarounds By China Shipping To US Through Other Countries

Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) sees FY2025 sales of $1.339 billion vs $1.29 billion analyst estimate.

Guidance

SRAD

Sportradar Gr Sees FY2025 Sales $1.339B vs $1.29B Est

Anheuser-Busch To Invest $300M In Its Facilities Across The US

AVTX

Avalo Therapeutics Q1 2025 EPS $(1.25) Beats $(1.39) Estimate, Cash On Hand Of Approximately $125 As Of March 31, 2025 Expected To Provide Runway Into 2027, With Optionality To Extend Into 2028

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) with a Buy and maintains $29 price target.

LQDA

HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target

Tiziana Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital.

TLSA

Tiziana Life Sciences Executive Chairman and Founder Gabriele Cerrone Increases Stake to 37.02% with 15,000 Share Purchase, Total Holding Reaches 43.25M

Personal-finance guru Ric Edelman says the United States is "failing its youngest investors," claiming that despite years of effort, "we spend a lot of time trying to improve financial literacy — we stink at it."
What Happened: Edelman, <a href="https://www.cnbc.com/2025/05/10/america-failing-its-young-investors-warns-financial-guru-ric-edelman-.html">speaking</a> with CNBC's "ETF Edge" argued that inadequate schooling leaves new graduates chasing zero-day options and crypto hype instead of long-term plans.
The Edelman Financial Engines founder points to a market that now sees retail traders driving roughly 45 percent of all U.S. options volume, per NYSE up from 34 percent before the pandemic, with half of that action concentrated in contracts that expire within five days.
A Wall Street Journal snapshot shows those ultra-short bets helped push overall options traffic to record highs in 2024, stoking what regulators call "gambling-style" <a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-12-23-2024/card/wall-street-s-hot-new-trade-is-fueling-gambling-addictions-8B5U0PU6XSbKMOl76VO7">risk</a>.
Younger Americans are also the group most likely to lose money to online-shopping fraud, reporting losses 86 percent more often than seniors, Federal Trade Commission data show. "When so many are getting their financial education from TikTok, that's a little scary," Edelman said, urging novice investors to seek vetted advice instead of social-media tips.
See also: <a href="https://www.benzinga.com/media/25/05/45342325/first-american-pope-leo-xiv-calls-artificial-intelligence-another-industrial-revolution">First American Pope Leo XIV Calls Artificial Intelligence Another Industrial Revolution</a>
Part of the fix, he insists, is early classroom instruction. Twenty-seven states now require a stand-alone personal-finance course for high-school graduation, up from 11 just four years ago, but millions of students in the rest of the country still learn about credit, insurance, and investing only "through the school of hard knocks."
Edelman also faults Wall Street for "complex, expensive" products that "make you a hostage rather than a customer" — an industry tilt he says pushes young savers toward get-rich-quick plays instead of diversified portfolios. To that end, he urges regulators to keep shining a light on steep-fee offerings and for employers to expand no-cost retirement counseling.
Why It Matters: While Edelman&#8217;s comments were directed at young investors, its safe to say that most Americans still stumble over basic money skills. FINRA's latest National Financial Capability Study found <a href="https://www.benzinga.com/personal-finance/25/04/45027948/only-4-of-americans-aced-this-7-question-financial-literacy-quiz-can-you">only 4%</a> aced all seven questions on its financial-literacy quiz, and modest gains on topics like inflation did little to lift the overall grade. The results reinforce calls for stronger classroom and workplace instruction.
That knowledge gap is costly. Consumers who don't understand interest often carry credit-card balances they can't afford, a dangerous habit with average rates near 20%, <a href="https://www.bankrate.com/credit-cards/advice/current-interest-rates/">according </a>to Bankrate. Personal-finance star Suze Orman <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/01/36800326/they-dont-have-a-clue-95-of-americans-struggle-with-financial-literacy-accord">pressed the point</a> on TV in early 2024, estimating that "probably 95%" of Americans are financially illiterate.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs</a>

Financial Advisors

Personal Finance

Personal Finance Guru Ric Edelman Says Wall Street's Complex Products Take Young Investors 'Hostage': 'Many Are Getting Their Financial Education From TikTok...'

Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.05 by 80 percent. The company reported quarterly sales of $327.29 million which beat the analyst consensus estimate of $306.42 million by 6.81 percent. This is a 13.34 percent increase over sales of $288.78 million the same period last year.

Sportradar Gr Q1 EPS $0.01 Misses $0.05 Estimate, Sales $327.29M Beat $306.42M Estimate

Press Releases

Exela Announces Plans to Spinoff Its BPA Business to Maximize Shareholder Value

Exela Technologies and AIDEO Technologies Enter Strategic Alliance

Exela Technologies Named a 2024 America's Greatest Workplace, Achieving Perfect 5-Star Ratings in Diversity and Mental Wellbeing

Exela Technologies, Inc. Reports Second Quarter 2024 Results

Exela Technologies, Inc. to Host Second Quarter 2024 Financial Results Conference Call

Reaktr.ai Launches AI-Powered SecAi Service on Oracle Cloud Infrastructure

Exela Technologies, Inc. to Host Third Quarter 2024 Financial Results Conference Call

Exela Technologies Recognized as a Strong Performer in Industry-Leading Task-Centric Automation Software Report

Exela Technologies, Inc. Announces Intention to Delist its Securities from Nasdaq and to Deregister its Securities under the Securities Exchange Act

Exela Technologies Announces Strategic Partnership with Michael Page

XELA

XELAP

Exela Technologies

Comments

Exela Technologies

Noticias

Últimas noticias sobre Exela Technologies (OTC:XELAP) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL